ENHERTU data from historic DESTINY-Breast04 trial in patients with HER2 low metastatic breast cancer has the potential to redefine how breast cancer is categorized and treated First presentation of DS-6000 and new patritumab deruxtecan results further support the strength of Daiichi Sankyo’s DXd ADC technology across multiple cancers including breast, lung, ovarian and renal cell … [Read more…]

A leader in outpatient imaging services to provide smart digital and self-service experiences with NICE CXone to improve services for patients, health systems and hospitals HOBOKEN, N.J.–(BUSINESS WIRE)–#NICE—NICE (Nasdaq: NICE) today announced that MedQuest Associates, a leading manager of outpatient diagnostic imaging facilities, has selected the NICE CXone Essentials Suite to enrich its services to … [Read more…]

ICON kick starts the first half of 2022 with a string of prestigious industry awards recognising healthcare intelligence work and staff, as independently judged by peers worldwide DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, has been recognised with … [Read more…]

– Lead Clinical Candidate, JK07, Demonstrates Favorable Safety and Further Promising Activity in Cohort 2 of Phase 1b Heart Failure with Reduced Ejection Fraction Study; Enrollment in Cohort 3 Now Ongoing – – Clinical Trial Application Submitted in Europe for Lead Oncology Program JK08, the first CTLA-4/IL-15 Antibody Fusion Protein, for the Treatment of Solid … [Read more…]

ENHERTU® (fam-trastuzumab deruxtecan-nxki) data will show the potential to improve survival for metastatic breast cancer patients and define a new segment of HER2-low disease Results from multiple trials further reinforce strength of industry-leading portfolio and pipeline, including novel combinations, across cancers with high unmet need WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca advances its ambition to redefine cancer care … [Read more…]

THRIVE-AA1 Study Meets Primary Endpoint for Scalp Hair Regrowth and Key Secondary Endpoints at Both Doses Statistically Significant Hair Regrowth Observed as Early as Eight Weeks CTP-543 Has Potential to be Best-in-Class for the Treatment of Alopecia Areata Topline Data from Second Phase 3 Trial, THRIVE-AA2, Expected Third Quarter of 2022 LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #AlopeciaAreata—Concert … [Read more…]

– New Exploratory Findings from 18-Month Analysis of HELIOS-A Suggest that Treatment with Investigational Vutrisiran May Benefit Patients with Hereditary ATTR (hATTR) Amyloidosis and Cardiac Involvement – – Improvements in NT-proBNP and Echocardiographic Parameters Seen in Cardiac Subpopulation – – Reductions in Technetium Uptake Observed in Patients with High Grade Uptake at Baseline – CAMBRIDGE, … [Read more…]

AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals (“Modra”) today announced that the company will present new data from its Phase 2b trial evaluating ModraDoc006/r, a boosted oral taxane therapeutic versus the standard-of-care IV chemotherapy docetaxel, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) at the upcoming ASCO General Annual Meeting held from June 3 – 7, 2022 virtually and … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “SOP Writing, Training and Compliance in the Pharmaceutical Industry” training has been added to ResearchAndMarkets.com’s offering. In this course you will learn the keys to writing effective SOPs, the vital connection between the documentation and training spheres, and how to maximize this connection to improve the quality of both SOPs and training. Standard … [Read more…]

Researchers Said Masimo PVi Can Be Used As a “Noninvasive, Rapid, and Objective Tool” for Helping Clinicians Predict Response to Treatment and Follow Up in Children with Obstructive Respiratory Disease NEUCHATEL, Switzerland–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the American Journal of Emergency Medicine in which Dr. Gülsah … [Read more…]